These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1310 related articles for article (PubMed ID: 16337046)

  • 1. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
    Roig E; Perez-Villa F; Morales M; Jiménez W; Orús J; Heras M; Sanz G
    Eur Heart J; 2000 Jan; 21(1):53-7. PubMed ID: 10610744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of microalbuminuria in chronic heart failure patients.
    van de Wal RM; Asselbergs FW; Plokker HW; Smilde TD; Lok D; van Veldhuisen DJ; van Gilst WH; Voors AA
    J Card Fail; 2005 Oct; 11(8):602-6. PubMed ID: 16230263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
    Tang WH; Vagelos RH; Yee YG; Fowler MB
    Am Heart J; 2004 Nov; 148(5):889-94. PubMed ID: 15523323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
    Lee AF; MacFadyen RJ; Struthers AD
    Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Level of angiotensin II and aldosterone in plasma is often elevated in patients with heart failure treated with converting enzyme inhibitors--preliminary results].
    Grzybowski J; Bilińska ZT; Janas J; Michalak E; Skwarek M; Ruzyłło W
    Przegl Lek; 2002; 59(8):587-9. PubMed ID: 12638326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
    Jorde UP; Vittorio TJ; Dimayuga CA; Homma S; Rizkala A; Le Jemtel TH; Katz SD
    Am J Cardiol; 2004 Dec; 94(12):1501-5. PubMed ID: 15589004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The influence of ACE inhibitors on urinary electrolyte secretion and the response to transitory hypovolemia in chronic heart failure].
    Marenzi G; Lauri G; Assanelli E; Grazi M; Guazzi M; Berna G; Salvioni A; Agostoni P
    Cardiologia; 1997 Dec; 42(12):1277-83. PubMed ID: 9534323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II exerts positive feedback on the intrarenal renin-angiotensin system by an angiotensin converting enzyme-dependent mechanism.
    Sadjadi J; Kramer GL; Yu CH; Welborn MB; Modrall JG
    J Surg Res; 2005 Dec; 129(2):272-7. PubMed ID: 15992826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.